PAMU
SUPN icon

Pictet Asset Management (UK)’s Supernus Pharmaceuticals SUPN Stock Holding History

Pictet Asset Management (UK)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$4.93M Sell
160,050
-127,286
-44% -$3.9M 0.01% 853
2021
Q1 		$7.52M Sell
287,336
-67,450
-19% -$1.89M 0.01% 738
2020
Q4 		$8.93M Sell
354,786
-23,100
-6% -$497K 0.01% 657
2020
Q3 		$7.88M Sell
377,886
-34,197
-8% -$776K 0.01% 616
2020
Q2 		$9.79M Sell
412,083
-39,300
-9% -$868K 0.02% 529
2020
Q1 		$8.12M Buy
451,383
+56,500
+14% +$1.19M 0.02% 517
2019
Q4 		$9.37M Sell
394,883
-49,049
-11% -$1.19M 0.02% 602
2019
Q3 		$12.2M Buy
443,932
+40,400
+10% +$1.2M 0.03% 489
2019
Q2 		$13.4M Sell
403,532
-68,581
-15% -$2.35M 0.03% 470
2019
Q1 		$16.5M Buy
472,113
+75,089
+19% +$2.79M 0.04% 441
2018
Q4 		$13.2K Buy
397,024
+36,680
+10% +$1.58M 0.03% 449
2018
Q3 		$18.1M Sell
360,344
-21,922
-6% -$1.08M 0.04% 435
2018
Q2 		$22.9M Sell
382,266
-130,549
-25% -$6.76M 0.05% 369
2018
Q1 		$23.5M Sell
512,815
-112,629
-18% -$4.7M 0.06% 352
2017
Q4 		$24.9M Buy
625,444
+134,161
+27% +$5.3M 0.06% 340
2017
Q3 		$19.7M Buy
491,283
+400,083
+439% +$17.3M 0.06% 368
2017
Q2 		$3.43M Buy
91,200
+6,100
+7% +$217K 0.01% 693
2017
Q1 		$2.66M Sell
85,100
-2,800
-3% -$75K 0.01% 731
2016
Q4 		$2.22M Buy
+87,900
New +$1.96M 0.01% 735
2015
Q1 		– Sell
-238,300
Closed -$1.98M – 888
2014
Q4 		$1.98M Buy
238,300
+10,900
+5% +$91.6K 0.01% 753
2014
Q3 		$1.98M Buy
+227,400
New +$2.05M 0.01% 737

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Pictet Asset Management (UK)'s SUPN Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Supernus Pharmaceuticals (SUPN) stake by 44% in Q2 2021, selling an estimated $3.9M and leaving 160,050 shares worth $4.93M. The position accounts for 0.01% of the portfolio, ranked #853.

Pictet Asset Management (UK) first reported a position in SUPN in Q3 2014 and has held it in 21 quarters since. The position peaked at $24.9M in Q4 2017. 226 funds tracked by Wall St. Rank hold SUPN as of Q2 2021.

  • Pictet Asset Management (UK) held 160,050 shares of Supernus Pharmaceuticals worth $4.93M as of Q2 2021.
  • Pictet Asset Management (UK) sold 127,286 Supernus Pharmaceuticals shares in Q2 2021, an estimated $3.9M.
  • Supernus Pharmaceuticals made up 0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #853 holding.
  • Pictet Asset Management (UK) first reported a position in Supernus Pharmaceuticals in Q3 2014 and has held it in 21 quarters since.
  • Pictet Asset Management (UK)'s Supernus Pharmaceuticals position peaked at $24.9M in Q4 2017.
  • 226 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.